We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Perspectives on Fluorinated Pyrimidine Use in Gastrointestinal and Breast Oncology

Jan 2, 2001
Volume: 
15
Issue: 
1

During this symposium, faculty
participated in a roundtable discussion of the relative merits and weaknesses
associated with use of the fluorinated pyrimidines. Dehydropyrimidine
dehydrogenase (DPD) deficiency and the impact of this deficiency on the efficacy
of fluorouracil-based therapies was a major focus of the discussion. Other
topics discussed included appropriate follow-up for patients receiving oral
therapy and reimbursement issues associated with oral vs intravenous therapy.

Roundtable Discussion
Participants

MODERATOR:

Leonard Saltz, MD

Memorial Sloan-Kettering Cancer Center, New York, NY

PANELISTS:

Al Benson, III, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern
University, Chicago, Illinois

Peter Danenberg, MD
University of Southern California, Los Angeles, California

Robert Diasio, MD
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama

Jean Grem, MD*
National Cancer Institute - Medical Branch, National Naval Medical
Center, Bethesda, Maryland

William Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern
University, Chicago, Illinois

Daniel Haller, MD
University of Pennsylvania, Philadelphia, Pennsylvania

Paulo Hoff, MD

The University of Texas M. D. Anderson Cancer Center, Houston, Texas

John Marshall, MD
Georgetown University, Washington, DC

Udo Vanhoefer, MD, PhD
University of Essen Medical School, Essen, Germany

Dehydropyrimidine Dehydrogenase Deficiency

Leonard Saltz, MD: In this general discussion, we’ll talk
about the direction in which we see oral fluorinated pyrimidines going. The
issues there are going to be in terms of their development.

Let’s go back to the creation. It’s day six. Human beings
are being created. You’re putting the person together and you throw in DPD.
Why? It’s fascinating to me that people who are DPD deficient live all their
lives without knowing it unless they are exposed to fluorouracil (5-FU).
Eniluracil is a phenomenally effective inhibitor and yet unbelievably nontoxic.
So what is this enzyme doing there?

Robert Diasio, MD: We talk about DPD and fluorouracil metabolism
as being a catabolic enzyme. But in terms of metabolism itself within the body,
we can also look upon DPD as being an anabolic enzyme and a synthetic enzyme in
that it is one of the enzymes responsible, eventually, for the synthesis of beta
alanine. Beta alanine has been suggested, by some people, at least, to be
potentially important as a neurogrowth factor, although the evidence is very
weak.

But there’s another symptom of DPD deficiency that’s been
described in children that results in growth and mental retardation. A number of
cases have been described, mainly in the Benelux countries (Belgium, The
Netherlands, and Luxembourg), where they happen to do amino acid analyses on all
newborns. They were the first to describe DPD deficiency. They discovered an
elevated peak and couldn’t explain what it was; it turned out to be uracil.
They found this to be associated with microcephaly, growth retardation,
developmental defects, and seizures in some of these children. So beta alanine
may have a role in terms of development. That’s why I would ask why DPD is
needed. It wasn’t put there just to cannibalize 5-FU.

Peter O’Dwyer, MD: What about other altered pyrimidines like
methyl uridine that are important metabolically, for which you still wouldn’t
want very high levels?

Dr. Diasio: It’s not clear. There’s very little information
about the role of these other pyrimidine compounds.

Jean Grem, MD: It’s even more complicated because there have
been cases described where there are two siblings who are both genotypically DPD
deficient and yet one of them has all these neurologic deficits and the other
one is perfectly normal. So it’s more complicated than simply asking why you
have DPD deficiency. For people who are absolutely deficient, it’s possible
that something else may be missing.

Dr. Diasio: At the molecular level, some of those mutations have
now been shown to be the same. Skipping of axon 14 actually has been shown to be
responsible. We’ve shown it in some of the 5-FU patients.

Leonard Saltz, MD: So patients who find out that they are DPD
deficient when they have a bad experience with 5-FU, presumably have a lesser
degree of dysfunction—but some function—because they don’t have
developmental abnormalities. Phenotypically, is there anything to alert
somebody?

Dr. Diasio: No. It’s a true pharmacogenetic syndrome.

Dr. Saltz: If it’s really pharmacogenetic, then it’s harder
to justify the existence of the enzyme in the first place. It may be something
you need early on and then it’s superfluous.

Dr. Diasio: Yes. It may be very important in fetal development.

Dr. Saltz: Except if that were true, we’d have to postulate
that the people who clinically had deficiencies have lost them somewhere along
the way; that they had to have had it to develop normally.

Dr. Diasio: Or they had an exogenous supply of beta alanine or
some of these other factors.

Dr. Grem: For these children there may be some in utero deficit
or dietary deprivation. All that isn’t really known. DPD protein is a huge
molecule and very complex, 33 iron atoms. Its substrates are these tiny
pyrimidine bases and it doesn’t seem logical that you would have this huge
enzyme to handle these little bases.

John Marshall, MD: Is it inducible? Can you change its
expression?

Dr. Diasio: Not really. Not in the same way as a number of other
enzymes that we traditionally think of as being inducible.

Dr. Saltz: We don’t understand the regulation of its
expression.

Peter Danenberg, MD: It’s likely that this enzyme also might
have some undiscovered role.

Dr. Diasio: We’ve looked at the homology to see if there’s
anything else. We wondered if it was related to other enzymes. It doesn’t seem
to share homology with a lot of these other enzymes. Going to the gene bank, we
haven’t been able to find a similarity.

Pages

  • 1
  • 2
  • 3
  • 4
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.